This response from AI may be of interest in members who are in or may be considering bio investments. The issue will be unique for each issue but this overview seems to be helpful in the decision-making process.
Gray
**My Inquiry: **
THERE IS SIGNIFICANT MEDICARE COVERAGE FOR PROCEDURES/MEDICATIONS WHICH ARE INTENDED TO EXTEND LIFE BUT ARE NOT DESIGNED TO CURE THE MALADY. ARE THERE DISCUSSION REGARDING CUTTING THE COVERAGE FOR THESE PROCEDURES OR TREATMENTS?
ChatGPT said:
While there are ongoing Medicare cost-control discussions—such as price negotiation for high-cost drugs and reducing low-value care—there’s no major proposal specifically targeting coverage cuts for life-extending procedures or medications, even if they aren’t curative.
1. Medicare Drug Price Negotiation (IRA)
- Starting 2028, Medicare Part B will negotiate prices on select high-cost drugs—many of which are life-prolonging therapies—but this is about lowering prices, not cutting access .
- The focus is on cost, not eliminating coverage for these life-extending meds.
2. OPPS and Site-Neutral Payment Adjustments
- CMS is proposing reductions in outpatient/hospital payment rates—like flattening reimbursements between hospital and clinic settings .
- These are payment reforms, not service eliminations. Providers will still perform these life-extending procedures; they’ll just receive less.
3. No Cuts in Budget Reconciliation or Sequestration Specifically Targeting Life-Prolonging Care
- The 2025 reconciliation debate may trigger automatic Medicare cuts (~$500 billion over 2026–34), but these would likely be across-the-board budget adjustments, not focused on life-extension technologies KFF.
- Proposals have focused more on eligibility, overpayments (especially in Medicare Advantage), or reforming Part D, not specific treatments.
4. Proposals Like “Project 2025”
- Think tanks (e.g., Heritage Foundation’s Project 2025) have suggested broader reforms: shifting to competitive bidding, privatization, site-neutral payments, and repealing drug negotiation—but again, that’s about cost structure, not denying access to life-extending care Investopedia.
5. Obesity & Weight-Loss Drugs: A Notable Exception
- Medicare has specifically decided not to expand coverage for anti-obesity drugs like Wegovy or Zepbound, even though they are life-improving, citing cost concerns (~$25–35 billion over 10 years) axios.com+3apnews.com+3apnews.com+3.
- However, those medications may still be covered if used for comorbid conditions like heart disease or diabetes—it’s a choice to restrict coverage there, not a sweeping cut to life-extending meds.
Bottom Line
- There’s currently no major push to cut access to life‑extending, non-curative Medicare services.
- Instead, policymakers are focused on:
- Lowering costs through price negotiation.
- Reducing inefficient reimbursement practices (OPPS/site-neutral reforms).
- Ensuring eligibility and plan integrity, especially in Medicare Advantage and Part D.
- The obesity drug decision shows that costly new life-improving treatments may face specific coverage barriers, but this isn’t part of a broad effort to reduce all life-extending care.